Drug Approval | January 26, 2024
Zydus receives USFDA’s final approval for Gabapentin Tablets, 300 mg and 600 mg
Gabapentin is indicated for the management of Postherpetic Neuraligia
Gabapentin is indicated for the management of Postherpetic Neuraligia
The registered capital of the newly founded company is € 50 million
Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant
The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union
Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer
This product has sales of about US$ 20 million in Europe
Produodopa is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe motor fluctuations
The bold, dynamic, and new logo unveiled in this process captures the essence of the 'Better Together' theme
Pimavanserin is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson disease psychosis
The certification underscores Venus Remedies Limited's adherence to stringent quality control measures
Subscribe To Our Newsletter & Stay Updated
